loading
Schlusskurs vom Vortag:
$136.21
Offen:
$136.1
24-Stunden-Volumen:
34,233
Relative Volume:
0.25
Marktkapitalisierung:
$2.60B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
53.64
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-2.16%
1M Leistung:
+13.86%
6M Leistung:
+17.01%
1J Leistung:
+30.74%
1-Tages-Spanne:
Value
$134.30
$137.00
1-Wochen-Bereich:
Value
$131.75
$143.13
52-Wochen-Spanne:
Value
$90.29
$143.13

Ligand Pharmaceuticals Inc Stock (LGND) Company Profile

Name
Firmenname
Ligand Pharmaceuticals Inc
Name
Telefon
858-550-7500
Name
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Name
Mitarbeiter
68
Name
Twitter
@Ligand_LGND
Name
Nächster Verdiensttermin
2025-02-18
Name
Neueste SEC-Einreichungen
Name
LGND's Discussions on Twitter

Vergleichen Sie LGND mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
LGND
Ligand Pharmaceuticals Inc
134.57 2.56B 152.42M 45.24M 6.97M 2.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
589.03 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.04 31.99B 3.81B -644.79M -669.77M -6.24

Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Eingeleitet Stifel Buy
2024-10-03 Eingeleitet Oppenheimer Outperform
2024-07-30 Eingeleitet RBC Capital Mkts Outperform
2021-04-14 Fortgesetzt Stephens Overweight
2021-02-04 Bestätigt H.C. Wainwright Buy
2020-10-06 Eingeleitet Barclays Overweight
2020-03-24 Herabstufung Argus Buy → Hold
2020-03-10 Eingeleitet Guggenheim Neutral
2020-02-06 Eingeleitet The Benchmark Company Buy
2019-09-19 Hochstufung Barclays Equal Weight → Overweight
2019-06-11 Eingeleitet Barclays Equal Weight
2019-05-03 Bestätigt H.C. Wainwright Buy
2019-03-06 Bestätigt H.C. Wainwright Buy
2018-10-29 Hochstufung ROTH Capital Neutral → Buy
2018-10-02 Bestätigt H.C. Wainwright Buy
2018-09-11 Bestätigt Argus Buy
2018-08-17 Eingeleitet Goldman Neutral
2018-08-08 Herabstufung ROTH Capital Buy → Neutral
2018-06-21 Eingeleitet Argus Buy
2017-12-27 Bestätigt H.C. Wainwright Buy
2017-09-05 Fortgesetzt H.C. Wainwright Buy
2016-10-05 Bestätigt H.C. Wainwright Buy
2016-08-05 Herabstufung Deutsche Bank Hold → Sell
2016-03-11 Eingeleitet Sidoti Buy
2016-03-03 Eingeleitet H.C. Wainwright Buy
Alle ansehen

Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten

pulisher
07:00 AM

Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan

07:00 AM
pulisher
Jul 23, 2025

What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastFree Buy/Sell Signal Notifications - Autocar Professional

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Ligand Pharmaceuticals Incorporated stock priceRapid growth trajectories - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 18, 2025

Is Ligand Pharmaceuticals Incorporated stock a growth or value playFree Capital Allocation Plans - beatles.ru

Jul 18, 2025
pulisher
Jul 17, 2025

Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada

Jul 17, 2025
pulisher
Jul 17, 2025

Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 17, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia

Jul 16, 2025
pulisher
Jul 16, 2025

Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛

Jul 15, 2025
pulisher
Jul 14, 2025

Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia

Jul 11, 2025
pulisher
Jul 11, 2025

Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 11, 2025
pulisher
Jul 11, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative

Jul 10, 2025
pulisher
Jul 10, 2025

Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire

Jul 10, 2025
pulisher
Jul 10, 2025

Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jul 09, 2025
pulisher
Jul 05, 2025

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Ligand’s LNHC concludes merger with CHRO - Yahoo Finance

Jul 03, 2025
pulisher
Jul 02, 2025

Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times

Jul 02, 2025
pulisher
Jul 02, 2025

Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com

Jul 02, 2025
pulisher
Jul 02, 2025

Ligand completes merger, Pelthos to launch molluscum treatment By Investing.com - Investing.com UK

Jul 02, 2025
pulisher
Jun 30, 2025

Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Growth-Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 24, 2025

Ligand Pharmaceuticals: How a Biotech Royalty Model Drives Sustainable Growth - AInvest

Jun 24, 2025
pulisher
Jun 20, 2025

Yousif Capital Management LLC Sells 181 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jun 20, 2025
pulisher
Jun 16, 2025

Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jun 16, 2025
pulisher
Jun 16, 2025

Wealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com

Jun 14, 2025

Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$114.12
price down icon 0.42%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):